Ticker Details
Evolus, Inc. Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex.
IPO Date:	February 5, 2018
Sector:	Healthcare
Industry:	Drug Manufacturers
Market Cap:	$439.25M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.39 | 3.48%
Avg Daily Range (30 D):	$0.22 | 3.67%
Avg Daily Range (90 D):	$0.17 | 3.25%

Institutional Daily Volume
Avg Daily Volume:	.64M
Avg Daily Volume (30 D):	.8M
Avg Daily Volume (90 D):	.92M

Trade Size
Avg Trade Size (Sh.):	108
Avg Trade Size (Sh.) (30 D):	74
Avg Trade Size (Sh.) (90 D):	87

Institutional Trades
Total Institutional Trades:	1,056
Avg Institutional Trade:	$1.36M
Avg Institutional Trade (30 D):	$.56M
Avg Institutional Trade (90 D):	$.92M
Avg Institutional Trade Volume:	.12M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.14M
Avg Closing Trade (30 D):	$.56M
Avg Closing Trade (90 D):	$1.09M
Avg Closing Volume:	102.09K

News

Jun 4, 2026 @ 11:00 AM AEON Biopharma to Present Data Demonstrating Struc... Source: Aeon Biopharma

May 22, 2026 @ 2:31 PM Regenerative Medicine's Newest Public Company Is B... Source: Usa News Group

Dec 28, 2025 @ 5:26 PM ANI Stock Is Up 49% This Past Year, Revenue Is Sur... Source: Jonathan Ponciano

Dec 19, 2025 @ 11:00 PM AEON Biopharma Reports Inducement Grants Under NYS... Source: Aeon Biopharma, Inc.

Mar 10, 2025 @ 8:53 PM Mixue Group's Splashy Debut, Kroger's Change, Stuf... Source: Dylan Lewis

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.67	$-.16	$
Diluted EPS	$-.67	$-.16	$
Revenue	$301.79M	$73.14M	$90.3M
Gross Profit	$199.35M	$48.9M	$59.29M
Net Income / Loss	$-43.42M	$-10.67M	$.13M
Operating Income / Loss	$-24.34M	$-6.85M	$4.22M
Cost of Revenue	$102.44M	$24.24M	$31.01M
Net Cash Flow	$-18.1M	$-4.03M	$10.3M
PE Ratio